Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.

After leaving academia, Vagelos spent 19 years at Merck, headquartered in his hometown ... company to make its river blindness treatment, ivermectin, free to African countries that could not ...

Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the Democratic Republic of the Congo, with an effectiveness of 84% in those who had ...

“One of them is from Merck and the other one is from Pfizer ... “The National Institutes of Health is doing a study called ACTIV-6 where it is studying ivermectin in a well-designed, ...

It comes a day after the UK medicines regulator approved a similar treatment from Merck Sharp and Dohme (MSD). Pfizer says it stopped trials early as the initial results were so positive.